Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
Asciminib Roll-over Study |
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase4 | Argentina Austria Bulgaria Canada China Czechia France Germany Italy Malaysia Mexico Oman Poland Portugal Russia South Korea Spain Turkey (Türkiye) United Kingdom United States Vietnam View all |
NCT04877522 |
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. |
Oligometastatic Prostate Cancer (OMPC) | Phase3 | Argentina Australia Austria Belgium Brazil Canada China Colombia Czechia France Germany Greece Hungary Israel Italy Japan Malaysia Mexico Netherlands Puerto Rico Singapore Slovakia Spain Switzerland Taiwan United Kingdom United States View all |
NCT05939414 |
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN |
IC-MPGN | Phase3 | Argentina Brazil Canada Czechia Denmark France Germany Greece India Israel Italy Japan Netherlands Poland Slovakia South Korea Spain Switzerland Taiwan Turkey (Türkiye) United Kingdom United States Vietnam View all |
NCT05755386 |
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. |
Lymphatic Malformations | Phase2, Phase3 | Argentina Australia Belgium Czechia France Germany Italy Netherlands Spain Switzerland United States View all |
NCT05948943 |
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN |
C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis | Phase3 | Argentina Brazil China France Germany Israel Italy Japan Spain Switzerland Turkey (Türkiye) United Kingdom United States View all |
NCT03955445 |